Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma
Pulmonary Pharmacology & Therapeutics · 2023
DOI: 10.1016/j.pupt.2022.102187 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2023. Verfasst von Panpan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Asthma, Rhinitis, Allergic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
INTRODUCTION: The aim of this study was to compare the efficacy and safety of 3 years of HDM subcutaneous immunotherapy (HDM-SCIT) in allergic asthma (AA) children with mono- and polysensitized. METHODS: This was a retrospective observational study, 51 AA children (aged 4-14 years) who had completed 3 years of standardized HDM-SCIT were enrolled in. Based on skin prick tests (SPT) and allergen-specific IgE antibody (sIgE) test results, children were classified into two groups: the monosensitized group (n = 31) and the polysensitized group (n = 20). Total asthma symptoms score (TASS), total medication score (TMS), visual analog scale (VAS) scores, fractional exhaled nitric oxide (FeNO), lung function parameters, and adverse reactions were evaluated before treatment and at 6 months, 1, 2, 3 years of HDM-SCIT. RESULTS: In terms of effectiveness, compared to baseline, TASS, TMS, VAS, FeNO and lung function parameters were significantly improved in both groups after 3 years of HDM-SCIT (all P 0.05) except PEF%pred at 6 months (P = 0.048). In terms of security, the number of adverse reactions in both groups also no statistical difference between the two groups (all P > 0.05). CONCLUSION: This study confirmed that no significant difference was observed in the clinical efficacy and safety of HDM-SCIT between mono-and polysensitized children with allergic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China. Electronic address: lucky9924@163.com.
- Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China. Electronic address: sunxin6@fmmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi Province
Zitieren
APA
Zhang, P., Jia, Y., Jing, Z., Huang, J., Wu, H., & Sun, X. (2023). Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2022.102187
Vancouver
Zhang P, Jia Y, Jing Z, Huang J, Wu H, Sun X. Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma. Pulmonary Pharmacology & Therapeutics. 2023. doi:10.1016/j.pupt.2022.102187
BibTeX
@article{Zhang2023,
author = {Zhang, Panpan and Jia, Yuanyuan and Jing, Zenghui and Huang, Jinli and Wu, Huajie and Sun, Xin},
title = {Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1016/j.pupt.2022.102187}
}
EUVIMED